All 12084

8/13/2019 All 12084

1/12

P O S I T I O N P A P E R

Unexplained recurrent fever: when is autoinflammation

the explanation?

T. Kallinich1,2

, M. Gattorno3

, C. E. Grattan4

, H. D. de Koning5

, C. Traidl-Hoffmann6,7

, E. Feist1,8

,K. Krause1,9, D. Lipsker10, A. A. Navarini11, M. Maurer1,9, H. J. Lachmann12 & A. Simon13

1Autoinflammation Reference Center Charite (ARC), Charite University Medicine Berlin; 2Department of Pediatric Pneumology and

Immunology, Charite University Medicine Berlin, Berlin, Germany; 3UO Pediatria II, G. Gaslini Institute, Genova, Italy; 4St Johns Institute of

Dermatology, St Thomas Hospital, London, UK; 5Department of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen,

The Netherlands; 6Department of Dermatology and Allergy Biederstein, Technische Universitat, Munich; 7ZAUM Center for Allergy and

Environment, Technische Universitat Munich/Helmholtz Center, Munich; 8Department of Rheumatology and Clinical Immunology, Charite

University Medicine Berlin, Berlin; 9Department of Dermatology and Allergy, Charite University Medicine Berlin, Berlin, Germany; 10Faculte

de Medecine, Universite de Strasbourg et Clinique Dermatologique, Hopitaux universitaires de Strasbourg, Strasbourg, France;11Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland; 12National Amyloidosis Centre, University College London

Medical School, London, UK; 13Department of General Internal Medicine, Nijmegen Institute for Infection, Inflammation and Immunology

(N4i), Centre for Immunodeficiency and Autoinflammation (NCIA), Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

To cite this article: Kallinich T, Gattorno M, Grattan CE, de Koning HD, Traidl-Hoffmann C, Feist E, Krause K, Lipsker D, Navarini AA, Maurer M, Lachmann HJ,

Simon A. Unexplained recurrent fever: when is autoinflammation the explanation? Allergy2013; 68: 285296.

Keywords

immunology; paediatrics; urticaria.

Correspondence

Dr. Tilmann Kallinich, Charite University

Medicine Berlin, Pediatric Pneumology and

Immunology, Augustenburger Platz 1,

13353 Berlin, Germany.

Tel.: +49-(0)30-450-566182

Fax: +49-(0)30-450-566931

E-mail: [email protected]

Accepted for publication 21 October 2012

DOI:10.1111/all.12084

Edited by: Thomas Bieber

Abstract

Recurrent fever can be the sole or leading manifestation of a variety of dis-

eases including malignancies, autoimmune diseases and infections. Because the

differential diagnoses are manifold, no formal guidelines for the approach of

patients with recurrent fever exists. The newly recognized group of autoinflam-

matory diseases are often accompanied by repetitive fever attacks. As these

episodes are frequently associated by a variety of divergent presentations, the

differentiation of other causes for febrile illnesses can be difficult. In this arti-cle, we first review disease entities, which frequently present with the symptom

of recurrent fever. In a next step, we summarize their characteristic pattern of

disease presentation. Finally, we analyse key features of autoinflammatory dis-

eases, which are helpful to distinguish this group of diseases from the other

causes of recurrent fever. Recognizing these symptom patterns can provide the

crucial clues and, thus, lead to the initiation of targeted specific diagnostic tests

and therapies.

Abbreviations

CANDLE, chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature; CAPS, cryopyrin-associated periodic

syndrome; CINCA, chronic infantile neurologic cutaneous and articular syndrome; CRP, C-reactive protein; DIRA, deficiency of the interleukin

receptor antagonist; DITRA, deficiency of Interleukin-36 receptor antagonist; HIDS, hyperimmunoglobulinaemia D with periodic fever

syndrome; FCAS, familial cold autoinflammatory syndrome; FUO, fever of unknown origin; FMF, familial Mediterranean fever; IL-1,

interleukin-1; IL-6, interleukin-6; MWS, MuckleWells syndrome; NOMID, neonatal onset multisystem inflammatory syndrome; PDC,

potentially diagnostical clues; PAPA, pyogenic arthritis, pyoderma gangrenosum and acne; PFAPA, periodic fever, aphthous stomatitis,

pharyngitis and adenitis syndrome; SAA, serum amyloid A; soJIA, systemic onset juvenile idiopathic arthritis; TNF-, tumour necrosis factor-;

TRAPS, TNF receptor-associated periodic syndrome.

Allergy68 (2013) 285296 2013 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd 285

Allergy

8/13/2019 All 12084

2/12

The rhythmic recurrence of disease is an age-old problem.

It puzzled ancient physicians who supposed the rhythm to

be controlled by cosmic influences

A number of factors suggest a unity of periodic disor-

ders: The cycles and episodes are of similar duration, theyusually are benign, they often begin in childhood, recur

unchanged for decades and heredity occasionally is evident.

There is an overlapping of symptoms and signs in many of

the disorders often great enough at times to confuse classi-

fication (from Periodic Disease (1))

Recurrent fever is common and can be the most promi-

nent symptom of various diseases. The conditions under-

lying recurrent fever are manifold, which is one of the

reasons why no formal guidelines for an evidence-based

approach to its management are currently available. As

individual episodes of recurrent fever are often of short

duration, many patients are symptom free when they are

reviewed by specialists who may come from a variety of

fields (e.g. paediatrics, immunology, rheumatology, infec-

tious diseases, cardiology, haematology and dermatology).

Thus, the evaluation of the patient is often biased

towards the taken history and evidence of chronic damage

rather than acute signs present only during symptomatic

attacks.

Fever is characterized by a nonphysiological increase

in body temperature due to an increased hypothalamic

set point. It often accompanies infections and other

pathological processes, where cytokines [e.g. interleukin-

1 (IL-1), tumour necrosis factor- (TNF-) and inter-

leukin-6 (IL-6)] mediate an increase in the hypothalamic

set point. To achieve a higher core temperature, the bodychanges its own heat production and heat loss mecha-

nisms (2, 3).

No firm definition of recurrent fever is currently estab-

lished. For reasons of practicability, the suggested definition

by Knockaert, who defined recurrent fever by at least two

episodes of fever separated by an (apparently) symptom-free

interval of at least 2 weeks (4), will be applied in this article.

This definition excludes, amongst others, conditions charac-

terized by intermittent fever with fever episodes occurring

with

8/13/2019 All 12084

3/12

per year can occur (10). This is by far the most common

reason for recurrent fever in this age group.

In malignancies, a variety of mechanisms, for example, the

production and release of cytokines by necrotic material and

batch-wise growing tumour cells are proposed to induce

recurrent fever (11). Especially in lymphomas and leukaemias,

which often present with B symptoms, elevated levels of the

endogenous pyrogens IL-1and IL-6 were observed (12).

Noninfectious inflammatory diseases are a diverse group of

disorders, of which the autoimmune diseases are the best rec-

ognized. Autoimmune diseases are classically thought to

induce antigen-specific proinflammatory processes, which

subsequently may result in the development of fever. Inter-

mittent courses, especially at disease onset, are frequently

observed, and thus, these diseases have to be considered in

patients with recurrent fever of unknown sources.

This group also comprises the autoinflammatory diseases,

which are the main subject of this article. Autoinflammatory

diseases are characterized by an often unprovoked cytokine-

driven inflammatory process, mediated by cells of the innate

immune system (see Box 1). Clinical features of these diseases

have recently been reviewed in detail (1315). As recurrence

of fever is one hallmark of a subgroup of autoinflammatorysyndromes, this group was also designated as hereditary fever

syndromes (Table 2). Within these diseases, the fever can dif-

fer in terms of type, duration, frequency, periodicity, first

onset, potential triggers and the associated symptoms

(Table 2). This will be discussed in more detail below.

In addition, there are also three other groups recognized in

FUO. These little three comprise benign hyperthermia, fac-

titious fever and drug fever (4).

In benign hyperthermia, the increase in body temperature

is due to an imbalance of heat production and heat loss

mechanisms with no change in the hypothalamic set point.

Thus, it does not fulfil the definition of fever (2). Given that

this condition can be observed frequently even in young chil-

dren, it is an important differential diagnosis in patients with

recurrent temperature increase (16).

Auto- (Munchausen syndrome) or allo-aggression (Mun-

chausen by proxy) can include factitious fever with recurrent

occurrence and thus must be considered in adults and children,

respectively, with recurrent fever of unknown source (17, 18).

Drug fever is an often-overlooked cause for fever; it occurs

as the sole or most prominent feature in about 35% of

adverse events in hospitalized patients (19). Pathophysiologi-

cal mechanisms of drug-induced fever have previously been

reviewed (20). Although drug fever is usually characterized

by a continuous fever, it can be recurrent, especially in multi-

drug using patients.

How to approach recurrent fever patients

Patients with recurrent fever of unknown source are often

difficult to diagnose. The differential diagnoses are manifold,

and therefore, an algorithm covering all possible causes

appears difficult, if not impossible, to construct.

Prospective studies from the Netherlands have provided

valuable lessons in the diagnostic approach to patients with

(nonrecurrent) FUO (21, 22). These studies demonstrated that

a carefully taken history, repeated physical examinations and

a restricted set of investigations can lead to potential diagnos-

tic clues (PDC). These clues include signs, symptoms and

abnormalities, which potentially point towards the underlying

cause and thus guide more specified tests.

In contrast to patients with FUO, the evaluation of patients

with recurrent fever often necessitates a different approach

since: (i) patients often consult a specialist during an attack-free

period, thus signs of acute inflammation might not be present;

(ii) the patient usually has a long history and many previous

diagnostic (and probably therapeutic) attempts have failed toprovide a conclusive explanation for the presented symptoms;

and, most importantly, (iii) episodes may be characterized by a

specific pattern. Recognition of these characteristic patterns

together with a limited number of obligatory investigations pro-

vides relevant clues for the origin of recurrent fever (see below),

which can then guide the choice of specific diagnostic tests.

Pattern recognition in recurrent fever of unknown

origin

Asking the right questions can identify patterns of recurrent

fever manifestations. The following list of questions will sup-

port a systematic approach to the differential diagnosis.

1 At what age did symptoms first appear?

2 What is the duration of the individual fever episodes?

3 What other symptoms are associated with the fever episodes?

4 What is the time interval between episodes (duration,

variable or fixed intervals)?

5 What can trigger or alleviate a fever episode?

6 How have symptoms developed over time?

7 Which treatments have been used and what was the

response?

8 Is there a family history; does the patient originate from

a certain ethnicity?

Table 1 Disease groups causing recurrent fever

Mechanism

Big three Little three Miscellaneous

Inflammatory,

infectious Inflammatory, noninfectious

Mostly

inflammatory

Mostly noninflammatory,

mostly no fever per definition

Various

mechanisms

Disease(groups)

Infections Autoimmunediseases

Autoinflammatorydisease

Malignancies Munchausen(by proxy)

Drugfever

Benignhyperthermia

E.g. central fever,dehydration

Groups of inflammatory and noninflammatory conditions potentially leading to recurrent fever.


Kallinich et al. Autoinflammation causes recurrent fever

8/13/2019 All 12084

4/12

Table 2 Characteristics of autoinflammatory syndromes with recurrent fever

Disease Gene

Three main

associated findings

Fever

Onset Duration

FMF MEFV Peritonitis

ArthritisPleuritis

First years of life 1272 h

HIDS MVK (mevalonate kinase) Lymphadenopathy

Arthralgias

Abdominal symptoms

First year of life 37 days

CAPS FCAS NLRP3/CIAS1 Cold-induced urticarial rash

Arthralgias

Conjunctivitis

First year of life Median 12 h

MWS Urticarial rash

Sensorineural hearing loss

Amyloidosis

Childhood If present 23 days

NOMID Neonatal onset exanthema

Neurologic symptoms

Arthropathy with exostosis

Neonatal If present varying

duration

TRAPS TNFRSF1A Migrating exanthemas

and myalgias

Periorbital oedema

and conjunctivitis

Peritonitis

First years of life Daysweeks

CANDLE (83, 84) PSMB8 Atypical neutrophilic dermatosis

Lipodystrophy

Delayed physical development

First weeks

to month of life

Daily high frequent

recurrent fever

DITRA (8588) IL36RN Generalized pustular psoriasis

General malaise

Hyperleucocytosis

Variable Variable

NLPR12-

associated

periodic fever

syndrome (89, 90)

NLRP12 Cold-induced episodes

Arthralgias

Urticarial rash

First year of life 210 days

Schnitzlers

syndrome

None Urticarial rash

IgM or IgG paraproteinemia

Bone pain

>50 years Mostly 13, but

varying

PFAPA None Aphthous ulcer

Cervical adenitis

(Sterile) pharyngitis

Median 4th year of life Median 4 days

soJIA None Arthritis

Rash

Serositis, lymphadenopathy,

organomegaly

75% before 10th year

of life

Weeks

AOSD None Arthralgias

Rash

Sore throat, lymphadenopathy,

splenomegaly

75% before 50th year

of life

Weeks

FMF, familial Mediterranean fever; HIDS, hyperimmunoglobulinaemia D with periodic fever syndrome (Mevalonate kinase deficiency); CAPS,

cryopyrin-associated periodic syndrome; FCAS, familial cold autoinflammatory syndrome; MWS, MuckleWells syndrome; NOMID, neonatal

onset multisystem inflammatory syndrome; TRAPS, TNF receptor-associated periodic syndrome; CANDLE, chronic atypical neutrophilic der-

matosis with lipodystrophy and elevated temperature; DITRA, deficiency of interleukin-36 receptor antagonist; PFAPA, periodic fever, apht-

hous stomatitis, pharyngitis and adenitis syndrome; soJIA, systemic onset juvenile idiopathic arthritis; AOSD, adult onset Stills disease;

DIRA, deficiency of the interleukin 1 (IL-1) receptor antagonist; PAPA, pyogenic arthritis, pyoderma gangrenosum and acne.

Only single cases of patients with CANDLE-, DITRA- and NLRP12-associated fever syndrome were described in the literature. These three

diseases are not discussed in detail in the text. Autoinflammatory syndromes not typically associated with recurrent fever (e.g. DIRA, PAPA)

are not mentioned in the table.

FCAS, MWS and NOMID show many phenotypical overlaps and are all caused by mutations in the NLRP3gene (cyropyrin), and thus these

entities are combined as CAPS.

Allergy68 (2013) 285296 2013 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd288

Autoinflammation causes recurrent fever Kallinich et al.

8/13/2019 All 12084

5/12

At what age did symptoms first appear?

In the young child, recurrent fever episodes are most likely

caused by the physiological susceptibility to infections. Usu-

ally signs of minor infections accompany these episodes; the

recurrent symptoms resolve during the first year of life with-

out any sequelae (Fig. 1A) (10). Febrile episodes in patients

with an inherited immunodeficiency usually also manifest

first in the (very) young child, but they are frequently

accompanied by severe infections not uncommonly caused

by opportunistic pathogens. Nonetheless, approximately20% of cases of primary immunodeficiency are diagnosed in

adulthood (23). In children, malignant disease, particularly

leukaemias [which are known to induce the synthesis of

pyrogenic interleukins (12)], neuroblastoma, retinoblastoma

and renal tumour, is most prevalent in the under 4-year-old

age group; after the 10th year of life, the prevalence of

malignancy then increases during the whole life span (24,

25). In childhood and early adulthood, systemic lupus

erythematosus is a common autoimmune disease accompa-

nied by fever; in later adulthood different systemic vasculiti-

des, for example, polymyalgia rheumatica also frequently

present with fever.

Most autoinflammatory diseases first manifest during early

childhood. But late onset of symptoms, in adolescence or

later, is seen in some patients (2630).

What is the duration of individual fever episodes?

Although the length of a single febrile episode can vary

between and within individuals, fever duration can be

helpful in pattern recognition. In patients with physio-logical susceptibility to infections, fever episodes are

generally short (35 days) and also depend on the dis-

ease-causing infectious agents. In contrast, fever episodes

in patients with immune deficiencies, autoimmune dis-

eases and malignancies are usually of a longer duration

(Fig. 2A).

Although autoinflammation can produce fever of almost

any duration, individual autoinflammatory disorders are

often associated with inflammatory episodes of characteristic

durations (see next section).

Ca

tegories

Specific

diseases

Physiologic susceptibility

of infections

Immunodeficiency

Malignancy

Autoimmune diseases

Years

Cyclic neutropenia

PFAPA

FMF

HIDS

FCAS

Muckle Wells Syndrome

NOMID/CINCA

TRAPS

Schnitzlers Syndrome

Systemic juvenile idiopathic

arthritis/Adults onset Stills disease

0 1 10 20 30 40 50 60 70 80

Figure 1 Age of disease onset. Age distribution of disease onset

according to disease groups (A) and specific diseases (B). Red

symbolizes likely, yellow possible and blue unlikely age of disease

manifestation. Systemic lupus erythematosus, dermatomyositis

and polymyositis, mixed connective tissue disease and polymyalgia

rheumatica are summarized as autoimmune diseases. Cyclic neu-

tropenia is included, because it is a rare but important immunodefi-

ciency, which mimics periodic fever syndromes and periodic fever,

aphthous stomatitis, pharyngitis and adenitis syndrome (PFAPA).



8/13/2019 All 12084

6/12

What other symptoms are associated with the fever episodes?

As shown in Fig. 3A, a variety of associated symptoms can be

helpful in classifying different disease groups. Recurrent minor

infections are usually associated with mild symptoms only;

malignancies are often accompanied by the occurrence of B

symptoms (besides fever weight loss, night sweats); and autoim-

mune diseases frequently involve multiple organs. Accompanying

symptoms can also point to certain autoinflammatory disorders.

What is the time interval between episodes (duration,

variable or fixed intervals)?

Usually, febrile episodes occur with varying time intervals

and are rather episodic than strictly periodic. Only rarely the

time interval is fixed, meaning that the symptom-free periods

are always of the same length. This phenomenon is usually

only observed in patients with cyclic neutropenia (31, 32) or

with periodic fever, aphthous stomatitis, pharyngitis and ade-

nitis (PFAPA) syndrome (33, 34).

It is also important to ask whether patients are completely

symptom free between the febrile episodes, or whether some

symptoms persist. Persistent symptoms are more likely in

case of malignancy or autoimmune disease. In many autoin-

flammatory diseases, patients can be completely symptom

free in the intervals, although in some diseases, symptomsmay persist.

What can trigger or alleviate a fever episode?

This question can be helpful in the identification of many dis-

eases and is especially important in patients with recurrent

infections or drug-induced fever.

How have symptoms developed over time?

A general worsening of the symptoms over time with an

increasing number of organ systems affected and generally

reduced well-being are more likely in autoimmune diseases or

malignancies. Although organ damage can eventually develop

over time in autoinflammatory diseases, the symptom com-

plex accompanying the febrile attacks remains usually fairly

constant.

Which treatments have been used and what was the

response?

Here, the response to antibiotics as well as anti-inflammatory

and immunosuppressant therapy is of special interest and

should be meticulously enquired about.

Ca

tegories

Specific

diseases

Physiologic susceptibilityof infections

Immunodeficiency

Malignancy

Autoimmune diseases

Cyclic neutropenia

PFAPA

FMF

HIDS

FCAS

0 1 2 3 4 5 6 7 14 28


NOMID/CINCA

TRAPS

Schnitzlers Syndrome

Days



Figure 2 Duration of fever attack. Average duration of febrile attacks according to disease groups (A) and specific diseases (B). The colours

symbolize the likelihood as described in Fig. 1.



8/13/2019 All 12084

7/12

Is there a family history; does the patient originate from a

certain ethnicity?

Recessive and dominant inheritance is well recognized in immune

deficiencies and autoinflammatory diseases. Autoinflammatory

disease especially segregates in certain ethnicities (see below).

Distinguishing between the different autoinflammatory

diseases using the above questions

The recognition of a pattern can be the first and most impor-

tant step to suspect and, later on, to diagnose an autoinflam-matory disease.

First onset of symptoms is in early childhood

In 90% of patients, symptoms of Familial Mediterranean

fever (FMF) start before the age of 20, in 75%, first symp-

toms are present before the age of 10 (35) (Fig. 1A).

The age of onset in cryopyrin-associated periodic syn-

dromes (CAPS) depends on the phenotype: per definition first

symptoms of neonatal onset multisystem inflammatory

disease (NOMID) also known as chronic infantile neuro-

logic cutaneous and articular syndrome (CINCA) start in

the neonatal period, but recurrent fever episodes may not be

the dominant feature. In 60% of cases, fever in patients with

familial cold autoinflammatory syndrome (FCAS) manifests

during the first days of life, and in nearly all patients, first

symptoms are present during the first half year (36, 37)

Nearly 90% of MuckleWells syndrome (MWS) cases present

in infancy (30, 38). Febrile symptoms of hyperimmunoglobu-

linaemia D with periodic fever syndrome (HIDS) also start

in early childhood, on average around the 6th month of life,

and disease onset during the first weeks of life has beenreported (39). Although first symptoms of TNF receptor-

associated periodic syndrome (TRAPS) occur at a mean age

of 3 years, first manifestations can occur anytime between

the neonatal period and adulthood (29). Periodic fever, apht-

hous stomatitis, pharyngitis and adenitis syndrome syndrome

patients usually exhibit first symptoms before their 5th birth-

day with a wide range of disease onset (1/412 years) (40).

Seventy-five per cent of patients with soJIA have their first

symptoms before the 10th year of age. Adult onset Stills dis-

ease (AOSD) is usually manifests during young adulthood

Categories

Specificdise

ases

Physiologic susceptibility

of infections

Immunodeficiency

Malignancy

Autoimmune diseases

Cyclic neutropenia

PFAPA

FMF

HIDS

FCAS


NOMID/CINCA

TRAPS

Schnitzler s Syndrome



Figure 3 Associated symptoms according to disease groups (A) and specific diseases (B). The colours symbolize the likelihood as described

in Fig. 1.



8/13/2019 All 12084

8/12

(75% below the 50th year of age). Schnitzlers Syndrome is a

classical example of an autoinflammatory disease character-

ized by recurrent fever, which only manifests in adulthood

(mean age of onset is 50 years) (41).

Duration of fever episode

In FMF, a main diagnostic criterion is the recurrence of

short attacks with a duration of 1272 h (42) (Fig. 2B). Short

episodes are also observed in FCAS with a mean duration of

12 h and a range of 1/272 h (36). In HIDS and PFAPA,

longer episodes of about 37 days are more common (33, 34,

43). In TRAPS, episodes frequently last for up to 3 weeks.

Here, associated fever is only present during the first days

and can be absent, particularly in adult patients (29). In

patients with MWS and NOMID, the length of symptomatic

episodes can vary, and fever is not found consistently. In

Schnitzlers, syndrome, recurrent fever is commonly present

for 13 days, but the pattern is variable (41). In soJIA and

AOSD, fever episodes usually continue to occur for several

weeks.

Accompanying symptoms

Familial Mediterranean fever is generally associated with a

rather limited but specific combination of symptoms caused

by serositis at different sites (peritonitis, pleurisy and arthri-

tis). In other autoinflammatory conditions, specific symptoms

and signs, such as sensorineural hearing loss in CAPS, migra-

tory myalgia in TRAPS, headache, mental retardation and

arthropathy with exostosis in CINCA/NOMID, can be

important diagnostic markers (Fig. 3C and Table 2). In so-

JIA and AOSD fever, the typical transient salmon-pink col-

oured rash can be the crucial diagnostic hint.

Time interval between fever episodes

Cyclic neutropenia (31, 32) or a PFAPA syndrome should be

considered when symptom-free periods are (almost) always

of the same length (33, 34). Whereas young children with

PFAPA often experience attacks every 34 weeks, adults

with persistent symptoms experience fewer attacks (33, 34,

44). A high frequency of attacks, for example every other

week, can be seen in FMF, but patients with symptom-free

intervals of years or even no (febrile) symptoms have also

been described (phenotype II FMF) (35, 45). In patients with

other autoinflammatory diseases, attacks usually occur at

longer time intervals and the frequency may also be influ-

enced by the presence of triggering factors.

Specific triggers are characteristic for certain

autoinflammatory diseases

In general, in all autoinflammatory disorders, inflammatory

episodes can be precipitated by emotional stress, exercise and

(minor) infections, as well as fatigue (29, 39, 43). Female

patients often notice a relationship with their menstrual cycle,

and characteristically, fever episodes in most of the autoin-

flammatory disorders occur less frequently during pregnancy,

but delivery often provokes an attack (46).

Some triggers may be more disease specific. Most impor-

tantly, cold can trigger symptoms in FCAS and MWS

patients (36, 47). Fever episodes triggered by active immuni-

zation are frequently observed in HIDS (39, 43).

Current data derived from comprehensive biochemicalanalyses in PFAPA patients suggest that exposure to envi-

ronmental agents, for example otherwise not pathogenic bac-

teria or viruses or parts of them, induces inappropriate

inflammatory responses leading to recurrent febrile episodes

in PFAPA patients (48).

Development of symptoms over time

The course of the disease should be analysed from two different

perspectives: (i) the characteristics and frequency of individual

attacks and (ii) the development of long-term consequences.

Young children with FMF often present with signs of recur-

rent fever only, and other typical features of the disease such a

relapsing serositis appear as they get older (49). In HIDS, a sig-

nificant decrease in attack frequency with increasing age is

observed, although attack frequency often increases just after

adolescence (39). Fever is a typical symptom in children with

TRAPS but may be absent during attacks in adults (29). Long-

term follow-up of children with PFAPA showed that most

patients improve over time and eventually show complete remis-

sion with a mean duration of disease of 6 years. In patients with

long disease duration, the frequency of febrile episodes

decreased significantly overtime (44). For the group of CAPS,

for example, FCAS, MWS and NOMID, no synoptic data on

age-related characteristics of the single episodes are available,

but in general, acute symptoms seem not to differ over time.

All (untreated) monogenic autoinflammatory fever syn-dromes are associated with the development of AA amyloi-

dosis, although the prevalence varies from very rare [in

FCAS and HIDS (34, 37)], 14% in TRAPS (50), 25% in

FMF (45) to approximately 30% in MWS (51). There are no

reported cases in NOMID, presumably because before mod-

ern treatment few patients lived long enough to develop this

complication. Cryopyrin-associated periodic syndrome-associ-

ated long-term consequences include sensorineural hearing

loss in MWS and NOMID and visual loss and meningitic

headaches as well as arthropathy with exostosis in NOMID

(Table 2). These specific symptoms can be the crucial hint in

making the right diagnosis.

Response to treatment

Inefficacy of antibiotics is often a clear clue for an autoin-

flammatory aetiology. Steroids will have some benefit in

many of the autoinflammatory diseases, although in general

it is only very effective in PFAPA, soJIA and AOSD and to

a lesser extent in HIDS (33, 34). Steroids have no beneficial

effects in classical FMF attacks (45). Response to adequate

colchicine therapy can confirm FMF (52). In many autoin-

flammatory disorders, specific IL-1 inhibitors induce dramatic

and complete resolution of signs and symptoms (5356).



8/13/2019 All 12084

9/12

Family history and ethnicity

Familial Mediterranean fever should be especially considered

in patients originating from countries of the eastern Mediter-

ranean basin, for example Israel, Turkey and Armenia (57),

but it also can occur in patients from other ethnicities (58,

59). Hyperimmunoglobulinaemia D with periodic fever syn-

drome is most prevalent in the Netherlands, Italy and

France. The majority of patients from other countries were

European or from European ancestry, but this may be likely

an ascertainment bias, reflecting the availability of diagnostic

testing (39). The other monogenic autoinflammatory diseases

can be found in patients from all over the world.

A family history may reveal the inheritance pattern, which

will point towards the right diagnosis. But a number of

aspects are important: (i) the disease penetrance may vary,

that is, not all mutation carriers are affected, (ii) especially in

NOMID, many patients harbour a de novo-mutation, thus no

other family member is affected (60) and (iii) there may be

variable expressivity, that is, individuals may present with

different symptoms of varying severity at a variable age ofonset, and milder disease presenting later may be missed in a

routinely taken history.

Next diagnostic steps if an autoinflammatory

syndrome is suspected

Acute phase response

In autoinflammatory diseases, inflammatory febrile episodes

are always accompanied by elevated levels of hepatic acute

phase proteins and leucocytosis. Subclinical inflammatory

responses can be detected in the symptom-free intervals in

many instances (6163). Signs of chronic inflammation, for

example organomegaly, growth retardation or chronic anae-mia, can occur. The discrepancy between highly elevated C-

reactive protein (CRP) and low to normal procalcitonin is

characteristic for PFAPA and FMF (64, 65). The phagocyte-

specific danger signals S100A8/9 and S100A12 are sensitive

biomarkers for the detection of (subclinical) inflammation in

patients with FMF, soJIA and CAPS; in certain circum-

stances, they might be superior to classically used markers

(66, 67). Ferritin levels are especially helpful in diagnosing

patients with soJIA and AOSD. Greatly elevated levels may

point to the life-threatening complication of a macrophage

activation syndrome.

Specific biochemistry markers

Slight increases in IgD serum concentrations can be found in

a number of autoinflammatory disorders as well as other

inflammatory diseases. Serum IgD levels in HIDS can be

markedly increased (34, 39, 40, 68). Other biomarkers, for

example, mevalonic acid activity and levels in the urine of

patients with HIDS, the production of IL-1 by cultured

monocytes in CAPS (69) and the serum level of soluble TNF

receptor 1 in TRAPS (70), are not generally available and

are performed mainly for research purposes. In Schnitzlers

syndrome, an IgM paraprotein is typically present (41).

Genetics

Molecular genetic diagnostic testing can confirm autoinflam-

matory disease (Table 2). A diagnostic flow chart for a

rational application of this cost-intensive approach has been

published (71).

Nonetheless, genetic tests must be interpreted in context,and a variety of issues should be considered when using

genetic analyses to diagnose autoinflammatory diseases:

1 Up to 20% of patients with FMF do not exhibit two

mutations within the MEFVgene (72, 73), but their clini-

cal course resembles that of patients with a combined het-

erozygous or homozygous mutations (74). On the other

hand, in certain ethnic groups, most subjects with two

mutations within the MEFVgene do not suffer from clin-

ical FMF (phenotype III FMF) (75, 76).

Another challenge in the interpretation of genetic results

are the occurrences of polymorphisms, especially of the

amino acid exchange at MEFV position 148 (77). Thus,

the diagnosis of FMF is still based on clinical grounds

(42); but the genetic analysis can have a significant value

in the confirmation of the suspected diagnosis and may

allow a prediction on the disease course (78).

2 In patients with CAPS, the frequency of a negative

genetic analysis of the NLRP3 gene varies according to

the subtype: in FCAS up to 10%, in MWS up to 25%

and in NOMID up to 50% of patients do not exhibit

mutations despite a characteristic clinical phenotype (60,

79).

3 TRAPS is defined as a disease caused by mutations

within the TNFRSF1A gene (70). Low-penetrance poly-

morphisms (R92Q or P46L) are usually of no clinical sig-

nificance, although R92Q is sometimes associated with a

milder disease phenotype, which responds to less intensivetreatments (80).

4 A definite diagnosis of mevalonate kinase deficiency or

HIDS can be established when the mevalonate kinase

deficiency is present. This can be determined directly by

biochemical testing (raised mevalonic acid in the urine

during a fever episode) or by genetic testing of the meval-

onate kinase gene (81). The most prevalent mutations are

V377I and I268T.

5 Like in FMF, patients exhibiting (some) clinical charac-

teristics for TRAPS and HIDS but with no mutations in

the relevant gene have been described (47, 82). It is cur-

rently a matter of debate whether these patients should

correctly be classified as autoinflammatory disorder not

otherwise specified.

Conclusions

The underlying causes of recurrent fever are manifold, and

their identification is challenging. Autoinflammatory disor-

ders often present with recurrent febrile attacks and conse-

quently have to be considered when evaluating a patient with

such a history of fever. Recognizing symptom patterns can

provide crucial clues and, thus, lead to the initiation of tar-

geted specific diagnostic tests and therapies.



8/13/2019 All 12084

10/12

Acknowledgment

We thank Nicole Klameth for excellent technical assistance

in generating the figures.

Authors contribution

All authors took part at the EAACI task force meeting on

autoinflammatory disease held January 2011 in Berlin and

were involved in the manuscript preparation.

Conflict of interest

None.

Supporting Information

Additional Supporting Information may be found in the

online version of this article:

Appendix S1. Box 2: Infectious diseases causing recurrent

fever in immunocompetent individuals.

References

1. Reimann HA. Periodic disease.Medicine

(Baltimore)1951;30:219245.

2. Dinarello CA, Gelfand JA. Harrisons Prin-

ciples of Internal Medicine. New York:

McGraw-Hill Publ. Co., 1998; 8490.

3. Kluger MJ, Bartfai T, Dinarello CA. New

York Academy of Sciences & Lovelace

Respiratory Research Institute. Molecular

Mechanisms of Fever. New York Academyof Sciences, 1998.

4. Knockaert DC. Recurrent fevers of

unknown origin. Infect Dis Clin North Am

2007;21:11891211.

5. Kastner DL, Aksentijevich I, Goldbach-

Mansky R. Autoinflammatory disease

reloaded: a clinical perspective. Cell

2010;140:784790.

6. Ryan ME, Ferrigno K, OBoyle T, Long SS.

Periodic fever and skin lesions caused by

disseminated Mycobacterium chelonae infec-

tion in an immunocompetent child. Pediatr

Infect Dis J1996;15:270272.

7. Lekstrom-Himes JA, Dale JK, Kingma DW,

Diaz PS, Jaffe ES, Straus SE. Periodicillness associated with EpsteinBarr virus

infection. Clin Infect Dis 1996;22:2227.

8. Cogswell FB. The hypnozoite and relapse in

primate malaria. Clin Microbiol Rev

1992;5:2635.

9. Notarangelo LD, Fischer A, Geha RS,

Casanova JL, Chapel H, Conley ME et al.

Primary immunodeficiencies: 2009 update.

J Allergy Clin Immunol 2009;124:

11611178.

10. Gruber C, Keil T, Kulig M, Roll S, Wahn

U, Wahn V. History of respiratory infections

in the first 12 yr among children from a

birth cohort. Pediatr Allergy Immunol

2008;19:505512.

11. Johnson M. Neoplastic fever. Palliat Med

1996;10:217224.

12. Kurzrock R. Cytokine deregulation in cancer.

Biomed Pharmacother2001;55:543547.

13. Henderson C, Goldbach-Mansky R. Mono-

genic autoinflammatory diseases: new

insights into clinical aspects and pathogene-

sis. Curr Opin Rheumatol2010;22:567578.

14. Gattorno M, Federici S, Pelagatti MA, Caorsi

R, Brisca G, Malattia C et al. Diagnosis and

management of autoinflammatory diseases in

childhood.J Clin Immunol2008;28(Suppl 1):

S73S83.

15. Masters SL, Simon A, Aksentijevich I,

Kastner DL. Horror autoinflammaticus: the

molecular pathophysiology of autoinflamma-

tory disease (*). Annu Rev Immunol

2009;27:621668.

16. Kallinich T, Keitzer R, Puskas E, Boldt F.

Exercise-induced hyperthermia in childhood:a case report and pilot study. Acta Paediatr

2009;98:12171219.

17. Trejo-Hernandez J, Loredo-Abdala A,

Orozco-Garibay JM. Munchausen syndrome

by proxy in Mexican children: medical,

social, psychological and legal aspects. Rev

Invest Clin 2011;63:253262.

18. Zenone T. Fever of unknown origin in adults:

evaluation of 144 cases in a non-university

hospital.Scand J Infect Dis2006;38:632638.

19. Roush MK, Nelson KM. Understanding

drug-induced febrile reactions. Am Pharm

1993;33:3942.

20. Patel RA, Gallagher JC. Drug fever.Phar-

macotherapy2010;30:5769.21. de Kleijn EM, van Lier HJ, van der Meer

JW. Fever of unknown origin (FUO) II.

Diagnostic procedures in a prospective

multicenter study of 167 patients. The

Netherlands FUO Study Group. Medicine

(Baltimore)1997;76:401414.

22. Bleeker-Rovers CP, Vos FJ, de Kleijn EM,

Mudde AH, Dofferhoff TS, Richter C et al.

A prospective multicenter study on fever of

unknown origin: the yield of a structured

diagnostic protocol. Medicine (Baltimore)

2007;86:2638.

23. Gathmann B, Grimbacher B, Beaute J,

Dudoit Y, Mahlaoui N, Fischer A et al. The

European internet-based patient and

research database for primary immunodefi-

ciencies: results 20062008.Clin Exp Immu-

nol2009;157(Suppl 1):311.

24. Magnani C, Gatta G, Corazziari I, Kramar-

ova E, Pastore G, Viscomi S et al. Childhood

malignancies in the EUROCARE study: the

database and the methods of survival analy-

sis. Eur J Cancer 2001;37:678686.

25. Robert Koch-Institut. Zentrum fur

Krebsregisterdaten, Krebs in Deutschland

2007/2008. http://www.gekid.de/, 2012.

26. Kumpfel T, Hoffmann LA, Rubsamen H,

Pollmann W, Feneberg W, Hohlfeld R et al.

Late-onset tumor necrosis factor receptor-

associated periodic syndrome in multiple

sclerosis patients carrying the TNFRSF1A

R92Q mutation. Arthritis Rheum

2007;56:27742783.

27. Tamir N, Langevitz P, Zemer D, Pras E,

Shinar Y, Padeh S et al. Late-onset familialMediterranean fever (FMF): a subset with

distinct clinical, demographic, and molecular

genetic characteristics. Am J Med Genet

1999;87:3035.

28. Savage T, Loftus BG, Tormey V,

McDermott MF, Moylett E. Tumor necrosis

factor receptor-associated periodic syndrome

(TRAPS) or familial Hibernian fever:

presentation in a four-day-old infant.J Clin

Rheumatol2008;14:342345.

29. Hull KM, Drewe E, Aksentijevich I, Singh

HK, Wong K, McDermott EM et al. The

TNF receptor-associated periodic syndrome

(TRAPS): emerging concepts of an autoin-

flammatory disorder. Medicine (Baltimore)2002;81:349368.

30. Leslie KS, Lachmann HJ, Bruning E,

McGrath JA, Bybee A, Gallimore JR et al.

Phenotype, genotype, and sustained response

to anakinra in 22 patients with autoinflam-

matory disease associated with CIAS-1/

NALP3 mutations. Arch Dermatol

2006;142:15911597.

31. Dale DC, Hammond WPT. Cyclic neutrope-

nia: a clinical review. Blood Rev 1988;2:178

185.

32. Dale DC, Bolyard AA, Aprikyan A. Cyclic

neutropenia. Semin Hematol 2002;39:8994.

33. Thomas KT, Feder HM Jr, Lawton AR,

Edwards KM. Periodic fever syndrome in

children. J Pediatr 1999;135:1521.

34. Padeh S, Brezniak N, Zemer D, Pras E,

Livneh A, Langevitz P et al. Periodic fever,

aphthous stomatitis, pharyngitis, and ade-

nopathy syndrome: clinical characteristics

and outcome. J Pediatr 1999;135:98101.

35. Samuels J, Aksentijevich I, Torosyan Y,

Centola M, Deng Z, Sood R et al. Familial

Mediterranean fever at the millennium

clinical spectrum, ancient mutations, and a

survey of 100 American referrals to the



8/13/2019 All 12084

11/12

National Institutes of Health.Medicine

(Baltimore) 1998;77:268297.

36. Hoffman HM, Wanderer AA, Broide DH.

Familial cold autoinflammatory syndrome:

phenotype and genotype of an autosomal

dominant periodic fever. J Allergy Clin

Immunol2001;108:615620.

37. Stych B, Dobrovolny D. Familial cold auto-

inflammatory syndrome (FCAS): character-

ization of symptomatology and impact on

patients lives. Curr Med Res Opin

2008;24:15771582.

38. Muckle TJ, Wells M. Urticaria, deafness,

and amyloidosis: a new heredo-familial

syndrome. Q J Med 1962;31:235248.

39. van der Hilst JC, Bodar EJ, Barron KS,

Frenkel J, Drenth JP, van der Meer JW

et al. Long-term follow-up, clinical features,

and quality of life in a series of 103 patients

with hyperimmunoglobulinemia D

syndrome. Medicine (Baltimore) 2008;87:301

310.

40. Feder HM, Salazar JC. A clinical review

of 105 patients with PFAPA (a periodic

fever syndrome). Acta Paediatr 2010;99:

178184.

41. de Koning HD, Bodar EJ, van der Meer

JW, Simon A. Schnitzler syndrome: beyond

the case reports: review and follow-up of 94

patients with an emphasis on prognosis and

treatment. Semin Arthritis Rheum

2007;37:137148.

42. Livneh A, Langevitz P, Zemer D, Zaks N,

Kees S, Lidar T et al. Criteria for the diag-

nosis of familial Mediterranean fever. Arthri-

tis Rheum 1997;40:18791885.

43. Drenth JP, Haagsma CJ, van der Meer JW.

Hyperimmunoglobulinemia D and periodic

fever syndrome the clinical spectrum in a

series of 50 patients. International Hyper-

IgD Study Group. Medicine (Baltimore)

1994;73:133144.

44. Wurster VM, Carlucci JG, Feder HM Jr,

Edwards KM. Long-term follow-up of chil-

dren with periodic fever, aphthous stomati-

tis, pharyngitis, and cervical adenitis

syndrome. J Pediatr 2011;159:958964.

45. Sohar E, Gafni J, Pras M, Heller H. Famil-

ial Mediterranean fever. A survey of 470

cases and review of the literature. Am J Med

1967;43:227253.

46. Akar S, Soyturk M, Onen F, Tunca M. The

relations between attacks and menstrual peri-

ods and pregnancies of familial Mediterranean

fever patients.Rheumatol Int2006;26:676679.

47. Aganna E, Hammond L, Hawkins PN,

Aldea A, McKee SA, van Amstel HK et al.

Heterogeneity among patients with tumor

necrosis factor receptor-associated periodic

syndrome phenotypes. Arthritis Rheum

2003;48:26322644.

48. Stojanov S, Lapidus S, Chitkara P, Feder H,

Salazar JC, Fleisher TA et al. Periodic fever,

aphthous stomatitis, pharyngitis, and adeni-

tis (PFAPA) is a disorder of innate immu-

nity and Th1 activation responsive to IL-1

blockade. Proc Natl Acad Sci USA

2011;108:71487153.

49. Padeh S, Livneh A, Pras E, Shinar Y, Lidar

M, Feld O et al. Familial Mediterranean

fever in the first two years of life: a unique

phenotype of disease in evolution. J Pediatr

2010;156:985989.

50. Aksentijevich I, Galon J, Soares M, Mans-

field E, Hull K, Oh HH et al. The tumor-

necrosis-factor receptor-associated periodic

syndrome: new mutations in TNFRSF1A,

ancestral origins, genotype-phenotype stud-

ies, and evidence for further genetic hetero-

geneity of periodic fevers. Am J Hum Genet

2001;69:301314.

51. Muckle TJ. The MuckleWells syndrome.

Br J Dermatol 1979;100:8792.

52. Kallinich T, Haffner D, Niehues T, Huss K,

Lainka E, Neudorf U et al. Colchicine use

in children and adolescents with familial

Mediterranean fever: literature review and

consensus statement. Pediatrics 2007;119:

e474e483.

53. Goldbach-Mansky R, Dailey NJ, Canna

SW, Gelabert A, Jones J, Rubin BI et al.

Neonatal-onset multisystem inflammatory

disease responsive to interleukin-1beta inhi-

bition. N Engl J Med2006;355:581592.

54. Bodar EJ, Kuijk LM, Drenth JP, van der

Meer JW, Simon A, Frenkel J. On-demand

anakinra treatment is effective in mevalonate

kinase deficiency. Ann Rheum Dis

2011;70:21552158.

55. Gattorno M, Pelagatti MA, Meini A, Obici

L, Barcellona R, Federici S et al. Persistent

efficacy of anakinra in patients with tumor

necrosis factor receptor-associated periodic

syndrome. Arthritis Rheum 2008;58:1516

1520.

56. Hashkes PJ, Spalding SJ, Giannini EH,

Huang B, Johnson A, Park G et al. Rilona-

cept for colchicine-resistant or -intolerant

familial Mediterranean Fever: a randomized

trial. Ann Internal Med 2012;157:533541.

57. Ben-Chetrit E, Levy M. Familial Mediterra-

nean fever. Lancet 1998;351:659664.

58. Stewart L, Tolmie J, Galea P, Touitou I.

Familial Mediterranean fever in a cold cli-

mate: read The Lancet. Lancet

2000;356:2154.

59. Tchernitchko DO, Gerard-Blanluet M,

Legendre M, Cazeneuve C, Grateau G,

Amselem S. Intrafamilial segregation analy-

sis of the p.E148Q MEFV allele in familial

Mediterranean fever. Ann Rheum Dis

2006;65:11541157.

60. Aksentijevich I, Nowak M, Mallah M, Chae

JJ, Watford WT, Hofmann SR et al. De

novo CIAS1 mutations, cytokine activation,

and evidence for genetic heterogeneity in

patients with neonatal-onset multisystem

inflammatory disease (NOMID): a new

member of the expanding family of pyrin-

associated autoinflammatory diseases. Arthri-

tis Rheum 2002;46:33403348.

61. Lachmann HJ, Sengul B, Yavuzsen TU,

Booth DR, Booth SE, Bybee A et al. Clini-

cal and subclinical inflammation in patients

with familial Mediterranean fever and in het-

erozygous carriers of MEFV mutations.

Rheumatology (Oxford) 2006;45:746750.

62. Korkmaz C, Ozdogan H, Kasapcopur O,

Yazici H. Acute phase response in familial


2002;61:7981.

63. Ben-Zvi I, Livneh A. Chronic inflammation

in FMF: markers, risk factors, outcomes

and therapy. Nat Rev Rheumatol2011;7:105

112.

64. Yoshihara T, Imamura T, Yokoi K, Shibata

M, Kano G, Osone S et al. Potential use of

procalcitonin concentrations as a diagnostic

marker of the PFAPA syndrome. Eur J

Pediatr2007;166:621622.

65. Yuksel S, Ekim M, Ozcakar ZB, Yalcnkaya

F, Acar B, Oztuna D et al. The value of

procalcitonin measurements in children with

familial Mediterranean fever. Rheumatol Int

2011; [Epub ahead of print].

66. Wittkowski H, Kuemmerle-Deschner JB,

Austermann J, Holzinger D, Goldbach-

Mansky R, Gramlich K et al. MRP8 and

MRP14, phagocyte-specific danger signals,

are sensitive biomarkers of disease activity in

cryopyrin-associated periodic syndromes.

Ann Rheum Dis 2011;70:20752081.

67. Kallinich T, Wittkowski H, Keitzer R, Roth

J, Foell D. Neutrophil-derived S100A12 as

novel biomarker of inflammation in familial


2010;69:677682.

68. Medlej-Hashim M, Petit I, Adib S, Chouery

E, Salem N, Delague V et al. Familial Medi-

terranean fever: association of elevated IgD

plasma levels with specific MEFV mutations.

Eur J Hum Genet 2001;9:849854.

69. Gattorno M, Tassi S, Carta S, Delfino L,

Ferlito F, Pelagatti MA et al. Pattern of

interleukin-1beta secretion in response to

lipopolysaccharide and ATP before and after

interleukin-1 blockade in patients with

CIAS1 mutations. Arthritis Rheum

2007;56:31383148.

70. McDermott MF, Aksentijevich I, Galon J,

McDermott EM, Ogunkolade BW, Centola

M et al. Germline mutations in the extracel-

lular domains of the 55 kDa TNF receptor,

TNFR1, define a family of dominantly

inherited autoinflammatory syndromes. Cell

1999;97:133144.

71. Gattorno M, Sormani MP, DOsualdo A,

Pelagatti MA, Caroli F, Federici S et al. A

diagnostic score for molecular analysis of



8/13/2019 All 12084

12/12

hereditary autoinflammatory syndromes with

periodic fever in children. Arthritis Rheum

2008;58:18231832.

72. Padeh S, Shinar Y, Pras E, Zemer D, Lange-

vitz P, Pras M et al. Clinical and diagnostic

value of genetic testing in 216 Israeli chil-

dren with Familial Mediterranean fever. J

Rheumatol2003;30:185190.

73. Cazeneuve C, Hovannesyan Z, Genevieve D,

Hayrapetyan H, Papin S, Girodon-

Boulandet E et al. Familial Mediterranean

fever among patients from Karabakh and

the diagnostic value of MEFV gene analysis

in all classically affected populations.Arthri-

tis Rheum 2003;48:23242331.

74. Kone-Paut I, Hentgen V, Guillaume-Czi-

trom S, Compeyrot-Lacassagne S, Tran TA,

Touitou I. The clinical spectrum of 94

patients carrying a single mutated MEFV

allele. Rheumatology (Oxford) 2009;48:840

842.

75. Kogan A, Shinar Y, Lidar M, Revivo A,

Langevitz P, Padeh S et al. Common MEFV

mutations among Jewish ethnic groups in

Israel: high frequency of carrier and pheno-

type III states and absence of a perceptible

biological advantage for the carrier state.

Am J Med Genet2001;102:272276.

76. Camus D, Shinar Y, Aamar S, Langevitz P,

Ben-Zvi I, Livneh A et al. Silent carriage of

two familial Mediterranean fever gene muta-

tions in large families with only a single iden-

tified patient.Clin Genet 2011;82:288291.

77. Marek-Yagel D, Bar-Joseph I, Pras E, Berk-

un Y. Is E148Q a benign polymorphism or a

disease-causing mutation? J Rheumatol

2009;36:2372.

78. Cazeneuve C, Sarkisian T, Pecheux C, Der-

vichian M, Nedelec B, Reinert P et al.

MEFV-gene analysis in Armenian patients

with Familial Mediterranean fever: diagnos-

tic value and unfavorable renal prognosis of

the M694V homozygous genotype-genetic

and therapeutic implications. Am J Hum

Genet 1999;65:8897.

79. Aksentijevich I, D Putnam C, Remmers EF,

Mueller JL, Le J, Kolodner RD et al. The

clinical continuum of cryopyrinopathies:

novel CIAS1 mutations in North American

patients and a new cryopyrin model. Arthri-

tis Rheum 2007;56:12731285.

80. Pelagatti MA, Meini A, Caorsi R, Cattalini

M, Federici S et al. Long-term clinical pro-

file of children with the low-penetrance

R92Q mutation of the TNFRSF1A gene.

Arthritis Rheum 2011;63:11411150.

81. Drenth JP, Cuisset L, Grateau G, Vasseur

C, van de Velde-Visser SD, de Jong JG et al.

Mutations in the gene encoding mevalonate

kinase cause hyper-IgD and periodic fever

syndrome International Hyper-IgD Study

Group. Nat Genet 1999;22:178181.

82. Simon A, Cuisset L, Vincent MF, van Der

Velde-Visser SD, Delpech M, van Der Meer

JW et al. Molecular analysis of the mevalo-

nate kinase gene in a cohort of patients with

the hyper-Igd and periodic fever syndrome:

its application as a diagnostic tool. Ann

Intern Med2001;135:338343.

83. Liu Y, Ramot Y, Torrelo A, Paller AS, Si

N, Babay S et al. Mutations in PSMB8

cause CANDLE syndrome with evidence of

genetic and phenotypic heterogeneity.Arthri-

tis Rheum 2011;64:895907.

84. Torrelo A, Patel S, Colmenero I, Gurbindo

D, Lendnez F, Hernandez A et al. Chronic

atypical neutrophilic dermatosis with lip-

odystrophy and elevated temperature (CAN-

DLE) syndrome. J Am Acad Dermatol

2010;62:489495.

85. Marrakchi S, Guigue P, Renshaw BR, Puel

A, Pei XY, Fraitag S et al. Interleukin-

36-receptor antagonist deficiency and gener-

alized pustular psoriasis. N Engl J Med

2011;365:620628.

86. Augey F, Renaudier P, Nicolas JF. General-

ized pustular psoriasis (Zumbusch): a French

epidemiological survey. Eur J Dermatol

2006;16:669673.

87. Zelickson BD, Muller SA. Generalized pus-

tular psoriasis. A review of 63 cases. Arch

Dermatol 1991;127:13391345.

88. Ohkawara A, Yasuda H, Kobayashi H,

Inaba Y, Ogawa H, Hashimoto I et al.

Generalized pustular psoriasis in Japan: two

distinct groups formed by differences in

symptoms and genetic background.Acta

Derm Venereol 1996;76:6871.

89. Borghini S, Tassi S, Chiesa S, Caroli F,

Carta S, Caorsi R et al. Clinical presentation

and pathogenesis of cold-induced autoin-

flammatory disease in a family with recur-

rence of an NLRP12 mutation. Arthritis

Rheum 2011;63:830839.

90. Jeru I, Duquesnoy P, Fernandes-Alnemri T,

Cochet E, Yu JW, Lackmy-Port-Lis M et al.

Mutations in NALP12 cause hereditary

periodic fever syndromes. Proc Natl Acad

Sci USA 2008;105:16141619.



All 12084

Documents

Transcript of All 12084